226 related articles for article (PubMed ID: 31161346)
1. Genome editing of human pancreatic beta cell models: problems, possibilities and outlook.
Balboa D; Prasad RB; Groop L; Otonkoski T
Diabetologia; 2019 Aug; 62(8):1329-1336. PubMed ID: 31161346
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-based genome editing in primary human pancreatic islet cells.
Bevacqua RJ; Dai X; Lam JY; Gu X; Friedlander MSH; Tellez K; Miguel-Escalada I; Bonàs-Guarch S; Atla G; Zhao W; Kim SH; Dominguez AA; Qi LS; Ferrer J; MacDonald PE; Kim SK
Nat Commun; 2021 Apr; 12(1):2397. PubMed ID: 33893274
[TBL] [Abstract][Full Text] [Related]
3. A critical review on therapeutic approaches of CRISPR-Cas9 in diabetes mellitus.
Bora J; Dey A; Lyngdoh AR; Dhasmana A; Ranjan A; Kishore S; Rustagi S; Tuli HS; Chauhan A; Rath P; Malik S
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3459-3481. PubMed ID: 37522916
[TBL] [Abstract][Full Text] [Related]
4. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
[TBL] [Abstract][Full Text] [Related]
5. Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development.
Millette K; Georgia S
Curr Diab Rep; 2017 Oct; 17(11):116. PubMed ID: 28980194
[TBL] [Abstract][Full Text] [Related]
6. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
8. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
9. Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research.
Hu M; Cherkaoui I; Misra S; Rutter GA
Front Endocrinol (Lausanne); 2020; 11():576632. PubMed ID: 33162936
[TBL] [Abstract][Full Text] [Related]
10. Human pluripotent stem cell based islet models for diabetes research.
Balboa D; Otonkoski T
Best Pract Res Clin Endocrinol Metab; 2015 Dec; 29(6):899-909. PubMed ID: 26696518
[TBL] [Abstract][Full Text] [Related]
11. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
12. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
13. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
14. New tools for experimental diabetes research: Cellular reprogramming and genome editing.
Otonkoski T
Ups J Med Sci; 2016 May; 121(2):146-50. PubMed ID: 27007444
[TBL] [Abstract][Full Text] [Related]
15. CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
Chaterji S; Ahn EH; Kim DH
Theranostics; 2017; 7(18):4445-4469. PubMed ID: 29158838
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
Zhang Y; Sastre D; Wang F
Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.
Wang Y; Wang S; Chen W; Song L; Zhang Y; Shen Z; Yu F; Li M; Ji Q
Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217854
[No Abstract] [Full Text] [Related]
18. Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination.
Martin RM; Ikeda K; Cromer MK; Uchida N; Nishimura T; Romano R; Tong AJ; Lemgart VT; Camarena J; Pavel-Dinu M; Sindhu C; Wiebking V; Vaidyanathan S; Dever DP; Bak RO; Laustsen A; Lesch BJ; Jakobsen MR; Sebastiano V; Nakauchi H; Porteus MH
Cell Stem Cell; 2019 May; 24(5):821-828.e5. PubMed ID: 31051134
[TBL] [Abstract][Full Text] [Related]
19. Human Induced Pluripotent Stem Cells in the Curative Treatment of Diabetes and Potential Impediments Ahead.
Dadheech N; James Shapiro AM
Adv Exp Med Biol; 2019; 1144():25-35. PubMed ID: 30569414
[TBL] [Abstract][Full Text] [Related]
20. CRISPR editing in biological and biomedical investigation.
Huang J; Wang Y; Zhao J
J Cell Physiol; 2018 May; 233(5):3875-3891. PubMed ID: 28786481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
